Jessica Donington, MD - Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.